Year: 2020

What to make of the markets today? We just wrapped up the second quarter, and the S&P 500 registered its best quarter in 70 years, gaining 20%. It was even more impressive as the gains came on the rebound from the worst losses since the Great Depression. We’ve had recessionary pressures thanks to COVID-19, and the sudden burst of positive sentiment, as it became clear that this time, there really is pent-up demand after a collapse.Looking at the historical pattern of stock market performance following bearish quarters, SunTrust Robinson chief market strategist Keith Lerner sees reason for continued optimism.“The weight …read more […]

Uncle Sam best come through with more stimulus checks, or else investors could be battered. …read more […]

(Bloomberg) — Bankrupt Hertz Global Holdings Inc. and its bondholders are squaring off over how to shrink its nearly half-a-million vehicle fleet. Market watchers say the outcome could upend the multi-billion dollar lease-backed ABS industry.The cars are housed in an entity linked to Hertz’s asset-backed securities and leased to the rental giant. Normally, when a company with ABS files for bankruptcy, it must choose to confirm or reject the entire master lease tied to the debt. If it keeps the lease, it has to continue making payments on the vehicles as it offloads them piecemeal. If it walks away, all …read more […]

(Bloomberg) — One of Wall Street’s hottest innovations is being hailed as the potential key to luring trillions of actively managed dollars to the booming market for exchange-traded funds. Yet two of the industry’s biggest players want no part of it for now.Vanguard Group and State Street Corp. say they’re in wait-and-see mode as active, non-transparent funds take their crucial first steps in the $4.3 trillion U.S. arena for ETFs.These products come with many of the benefits of traditional ETFs but drastically reduced disclosure requirements. That makes so-called ANTs a likely conduit to bring stock-picking strategies to the exchange-traded universe.The …read more […]

Tigress Financial Partners Chief Investment Officer Ivan Feinseth joins Yahoo Finance’s Zack Guzman to discuss his outlook on the markets as new Pfizer data sparks coronavirus vaccine optimism. …read more […]

Committee for a Responsible Federal Budget Senior Vice President Marc Goldwein joins Yahoo Finance’s Zack Guzman to discuss how the coronavirus stimulus could impact U.S. debt, along with trust funds like Social Security. …read more […]

It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL (complete response letter) for its experimental post-operative pain medication, HTX-011.Following the verdict, Stifel analyst Derek Archila acknowledges that the current sentiment surrounding HRTX is negative, but he remains optimistic about the candidate.“While we think investors are losing confidence/patience with HRTX on getting HTX-011 over the goal line (2 CRLs and a PDUFA extension), the issues raised by the FDA in the CRL appear to be of a minor nature, and management’s commentary on the conference call make …read more […]

Progress in reopening stores may be reversed as coronavirus cases spike in certain states. …read more […]

…read more […]

…read more […]

If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Qualcomm Inc (NASDAQ:QCOM) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […] …read more […]

If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Intuit Inc (NASDAQ:INTU) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […] …read more […]

The frantic global search for a vaccine or therapy for the coronavirus has sent the valuations of previously small cap biotechs to unimagined heights over a short period of time. There can’t be many better examples for the phenomenon than Inovio Pharmaceuticals (INO). Investors have cheered the progress of its COVID-19 DNA vaccine candidate INO-4800 by sending shares on a mightily impressive run – the stock is up by 505% since the turn of the year (even after today’s 25% sell off).The massive gains, the richly valued $3.2 billion market cap and a track record that – while promising – …read more […]

The U.S. economy is expected to have added millions more payrolls in June from May, as regions across the country eased social distancing restrictions and allowed more businesses to reopen. …read more […]

Is it bye-bye to Macy’s if a COVID-19 second wave happens? …read more […]